| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011484415 |
| P356 | DOI | 10.1186/S12885-016-2199-Z |
| P932 | PMC publication ID | 4772351 |
| P698 | PubMed publication ID | 26925841 |
| P2093 | author name string | Yin Liu | |
| Sarah E Woodfield | |||
| Kathleen A Scorsone | |||
| Linna Zhang | |||
| Peter E Zage | |||
| P2860 | cites work | Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients | Q24294421 |
| The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins | Q24324729 | ||
| Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study | Q24658339 | ||
| Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors | Q27653491 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| Mammalian MAP kinase signalling cascades | Q28204140 | ||
| Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture | Q28245251 | ||
| A synthetic inhibitor of the mitogen-activated protein kinase cascade | Q28367955 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 | Q28609120 | ||
| Mitogen-activated protein kinase pathways | Q29618431 | ||
| Establishment and characterization of human neuroblastoma cell lines | Q31202789 | ||
| Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma | Q33861173 | ||
| NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome | Q34031980 | ||
| Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial | Q34446661 | ||
| Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways | Q35729391 | ||
| UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors | Q36480984 | ||
| Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations | Q36641925 | ||
| Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial | Q37658501 | ||
| MEK inhibitors: a patent review 2008 – 2010 | Q37872791 | ||
| Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition | Q38832429 | ||
| GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. | Q39034764 | ||
| Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models | Q39755197 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Human neuroblastomas and abnormalities of chromosomes 1 and 17. | Q40222319 | ||
| Neurofibromatosis type 1 gene mutations in neuroblastoma | Q41579794 | ||
| Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma | Q42754992 | ||
| Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour | Q42799715 | ||
| Human neuroblastoma cells and 13-cis-retinoic acid. | Q42818963 | ||
| Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies. | Q48648618 | ||
| Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition | Q50335943 | ||
| Transient MEK inhibitor-associated retinopathy in metastatic melanoma. | Q50455744 | ||
| Cytogenetic features of human neuroblastomas and cell lines. | Q52733297 | ||
| Biological classification of cell lines derived from human extra-cranial neural tumors | Q53523979 | ||
| A full-length 3D structure for MAPK/ERK kinase 2 (MEK2) | Q54595233 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuroblastoma | Q938205 |
| P304 | page(s) | 172 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression | |
| P478 | volume | 16 |
| Q64121696 | Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation |
| Q92073835 | Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response |
| Q90367882 | Management of pediatric low-grade glioma |
| Q90085168 | Multifocal primary neuroblastoma tumor heterogeneity in siblings with co-occurring PHOX2B and NF1 genetic aberrations |
| Q37745480 | Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. |
| Q38710561 | Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. |
| Q92618072 | Neurofibromin 1 expression is negatively correlated with malignancy and prognosis of epithelial ovarian cancer |
| Q89128864 | Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation |
| Q30238693 | Overview and recent advances in the treatment of neuroblastoma |
| Q92240963 | Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma |
| Q64970891 | Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma. |
| Q95840082 | Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways |
| Q90312207 | Role of GOLPH3 and TPX2 in Neuroblastoma DNA Damage Response and Cell Resistance to Chemotherapy |
| Q52597787 | Too many targets, not enough patients: rethinking neuroblastoma clinical trials. |
Search more.